Medical Treatment of Subjects with Gender Identity Disorder: The Experience in an Italian Public Health Center

International Journal of Transgenderism

Volumn 15, Issue 2, 2014, Pages 53-65

  Manieri, Chiara ^a   Castellano, Elena ^a   Crespi, Chiara ^a   Di Bisceglie, Cataldo ^a   Dell'Aquila, Carlotta ^a   Gualerzi, Anna ^a   Molo, Mariateresa ^b  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b Molo ONLUS   (Italy)

Author keywords

androgens; antiandrogens; cross sex hormonal therapy; estrogens; Gender identity disorder; quality of life

Indexed keywords

EID: 84905714838     PISSN: 15532739     EISSN: 14344599     Source Type: Journal    
DOI: 10.1080/15532739.2014.899174     Document Type: Article

References (21)

1. Asscheman, H., Giltay, E.J., Megens, J.A., de Ronde, W.P., van Trotsenburg, M.A., & Gooren, L.J. (2011). A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology, 164, 635-642.
2. Bockting, W. (2008). Psychotherapy and the real-life experience: From gender dichotomy to gender diversity. Sexologies, 17, 211-224.
3. Elamin, M.B., Garcia, M.Z., Murad, M.H., Erwin, P.J., & Montori, V.M. (2010). Effect of sex steroid use on cardiovascular risk in transsexual individuals: A systematic review and meta-analyses. Journal of Clinical Endocrinology, 72, 1-10.
4. Godano, A., Maggi, M., Jannini, E., Meriggiola, M.C., Ghigo, E., Todarello, O., Manieri, C. (2009). SIAMS-ONIG Consensus on hormonal treatment in gender identity disorders. Journal of Endocrinological Investigation, 32, 857-864.
5. Gómez-Gil, E., Zubiaurre-Elorza, L., Esteva, I., Guillamon, A., Godás, T., Cruz Almaraz, M., Salamero, M. (2011). Hormone-treated transsexuals report less social distress, anxiety and depression. Psychoneuroendocrinology, 37, 662-670.
6. Gooren, L. J., & Giltay, E.J. (2008). Review of studies of androgen treatment of female-to-male transsexuals: Effects and risks of administration of androgens to females. Journal of Sexual Medicine, 4, 765-776.
7. Gooren, L.J., Giltay, E.J., & Bunck, M.C. (2008). Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience. Journal of Clinical Endocrinology and Metabolism, 93, 19-25.
8. Gorin-Lazard, A., Baumstarck, K., Boyer, L., Maquigneau, A., Gebleux, S., Penochet, J.C., Bonierbale, M. (2012). Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. Journal of Sexual Medicine, 9, 531-541.
9. Hembree, W. C., Cohen-Kettenis, P., Delemarre-van de WaalH. A., Gooren, L. J., Meyer, W. J., 3rd, Spack, N. P., Montori, V. M,. (2009). Endocrine treatment of transsexual persons: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 94, 3132-3154
10. Jacobeit, J.W., Gooren, L.J., & Schulte, H.M. (2009). Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. European Journal of Endocrinology, 161, 795-798.
11. Meriggiola, M.C., Armillotta, F., Costantino, A., Altieri, P., Saad, F., Kalhorn, T., Pelusi, G. (2008). Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. Journal of Sexual Medicine, 5, 2442-2453.
12. Meriggiola, M.C., & Berra, M. (2012). Long-term cross-sex hormone treatment is safe in transsexual subjects. Asian Journal of Andrology, 14, 813-814.
13. Moore, E., Wisniewski, A., & Dobs, A. (2003). Endocrine treatment of transsexual people: A review of treatment regimens, outcomes, and adverse effects. Journal of Clinical Endocrinology and Metabolism, 88, 3467-3473.
14. Motmans, J., Meier, P., Ponnet, K., & T'Sjoen, G. (2012). Female and male transgender quality of life: Socioeconomic and medical differences. Journal of Sexual Medicine, 9, 743-750.
15. Mueller, A., Kiesewetter, F., Binder, H., Beckmann, M., & Dittrich, R. (2007). Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. Journal of Clinical Endocrinology and Metabolism, 92, 3470-3475.
16. Nott, S.L., Huang, Y., Fluharty, B.R., Sokolov, A.M., Huang, M., Cox, C., & Muyan, M. (2008). Do estrogen receptor beta polymorphisms play a role in the pharmacogenetics of estrogen signaling? Current Pharmacogenomics and Personalized Medicine, 6, 239-259.
17. Ott, J., Kaufmann, U., Bentz, E.K., Huber, J.C., & Tempfer, C.B. (2010). Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertility and Sterility, 93, 1267-1272.
18. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. (2002). Circulation, 106, 3143-3421.
19. Traish, A.M., & Gooren, L.J. (2010). Safety of physiological testosterone therapy in women: Lessons from female-to-male transsexuals treated with pharmacological testosterone therapy. Journal of Sexual Medicine, 7, 3758-3764.
20. Van Kesteren, P.J., Asscheman, H., Megens, J.A., & Gooren, L.J. (1997). Mortality and morbidity in transsexual subject treated with cross-sex hormones. Journal of Clinical Endocrinology, 47, 337-342.
21. Zitzmann, N., & Nieschlag, E. (2007). Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 92, 3844-3853.